Skip to main content
SpringerLink
Log in

Irinotecan als Ergänzung zu LV5FU2 bringt keinen Überlebensvorteil

  • Journal Club / Kolonkarzinom
  • Adjuvante Chemotherapie des Kolonkarzinoms im Stadium III
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Hämatologie und Onkologie, Klinikum, Braunschweig, Deutschland

    Florian Lordick

Authors
  1. Florian Lordick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Lordick.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lordick, F. Irinotecan als Ergänzung zu LV5FU2 bringt keinen Überlebensvorteil. Info Onkol. 13, 20–21 (2010). https://doi.org/10.1007/BF03362780

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03362780

Schlüsselwörter

Search

Navigation